Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial...
Transcript of Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial...
![Page 1: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/1.jpg)
1
Faculty Disclosure Information
• I have no financial relationship with any manufacturer of any commercial product and/or provider of commercial services discussed in the CME activity.
• I do not intend to discuss an unapproved/investigative use of a commercial product or device in
• my presentation.
![Page 2: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/2.jpg)
2
Objectives
• Learn the developmental processes that contribute to the formation of the lung’s airways, airspaces and vessels
• Understand the functional implications of disordered lung development
Laws of Lung Development
• Law 1. The bronchi and broncioli develop by 16 weeks.
• Law 2. The alveoli multiply from 20 x 106 to 300 x 106 postnatally.
• Law 3. Preacinar arteries appear with the airways; intra-acinar arteries with the alveoli.
![Page 3: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/3.jpg)
3
![Page 4: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/4.jpg)
4
FETUS
![Page 5: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/5.jpg)
5
![Page 6: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/6.jpg)
6
NEWBORN LUNG DISEASE
• DEVELOPMENTAL DISORDERS
- Growth
- Maturation
• ACQUIRED
- Iatrogenic
- Infection
• OTHER
- Meconium aspiration
- Massive hemorrhage
- Chronic pneumonitis
- Neuro-endocrine hyperplasia of infancy (NEHI)
Disorders of lung growth-Airways/Air passages
• Hypoplasia/aplasia
• Bronchial atresia
• Acinar dysplasia
• Congenital pulmonary adenomatoid malformation (CPAM)
• Sequestration
• Congenital lobar emphysema (CLE)
![Page 7: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/7.jpg)
7
Disorders of lung growth- Vessels
• Abnormal vascular growth –PPHN /MAS
• Alveolar capillary dysplasia (ACD)/misalignment of vessels
• Congenital pulmonary lymphangiectasia
Disorders of lung maturation
• Prematurity–deficiency of surfactant lipid and protein (HMD & SP-A deficiency)
• Pulmonary interstitial glycogenosis (PIG)
• Congenital alveolar proteinosis
- SP-B deficiency
- SP-C deficiency
- GM-CSF mutation
- ABCA3 mutation
![Page 8: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/8.jpg)
8
Disorders of lung growth-Airways/Air passages
• Hypoplasia/aplasia
• Bronchial atresia
• Acinar dysplasia
• Congenital pulmonary adenomatoid malformation (CPAM)
• Sequestration
• Congenital lobar emphysema (CLE)
Lung hypoplasia - causes
• Prolonged oligohydramnios
• Renal agenesis
• Renal cystic disease
• Obstruction of the lower urinary tract
• P.R.O.M.
• Skeletal dysplasia
![Page 9: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/9.jpg)
9
Lung hypoplasia - analysis
• Lung weight < 50% N.E.W
• Lung weight:body weight N= 0.012
• Reduced bronchial generations
• Decreased radial alveolar count
• Reduced alveolar number
• Reduced number of air-blood barriers
• Reduced number of intra-acinar arteries
Lung hypoplasia - causes
• Prolonged oligohydramnios
• Renal agenesis
• Renal cystic disease
• Obstruction of the lower urinary tract
• P.R.O.M.
• Skeletal dysplasia
![Page 10: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/10.jpg)
10
Lung hypoplasia - analysis
• Lung weight < 50% N.E.W
• Lung weight:body weight N= 0.012
• Reduced bronchial generations
• Decreased radial alveolar count
• Reduced alveolar number
• Reduced number of air-blood barriers
• Reduced number of intra-acinar arteries
Clinical Summary
• Term boy with MCA and DNR status
• Dandy-Walker anomaly
• CDH – left lobe of liver, stomach, small bowel and spleen in left thoracic cavity
![Page 11: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/11.jpg)
11
![Page 12: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/12.jpg)
12
Disorders of lung growth-Airways/Air passages
• Hypoplasia/aplasia
• Bronchial atresia
• Acinar dysplasia
• Congenital pulmonary adenomatoid malformation (CPAM)
• Sequestration
• Congenital lobar emphysema (CLE)
![Page 13: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/13.jpg)
13
![Page 14: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/14.jpg)
14
Pathologic features- CPAM
0 1 2 3 4
Frequency
%1-3 >65 20-25 8 2-4
Cyst size cm
0.5 10 2.5 2 7
Pathologic features
Bronchial Fibrous septa
Bronchioles Solid Alveolar lining
Mucous cells
Present 100%
Present 33%
Absent Absent Absent
![Page 15: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/15.jpg)
15
![Page 16: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/16.jpg)
16
Type 1 CPAM
![Page 17: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/17.jpg)
17
Type 1 CPAM
Disorders of lung growth-Airways/Air passages
• Hypoplasia/aplasia
• Bronchial atresia
• Acinar dysplasia
• Congenital pulmonary adenomatoid malformation (CPAM)
• Sequestration
• Congenital lobar emphysema (CLE)
![Page 18: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/18.jpg)
18
![Page 19: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/19.jpg)
19
![Page 20: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/20.jpg)
20
![Page 21: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/21.jpg)
21
Disorders of lung growth- Vessels
• Abnormal vascular growth –PPHN /MAS
• Alveolar capillary dysplasia (ACD)/misalignment of vessels
• Congenital pulmonary lymphangiectasia
PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN
(PPHN)
• Precocious muscularization -genetic- stress-ductal constriction
• Pulmonary hypoplasia• vasoactive agents
![Page 22: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/22.jpg)
22
Clinical Summary
• 3 d old term boy, CS – TMC
• RDS & PPHN
• Transferred to PCH for ECMO
• Expired before ECMO could be initiated
![Page 23: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/23.jpg)
23
Lung Barium Angiogram
Processes involved in vessel development
ANGIOGENESIS - the sprouting of vessels from preexisting ones
VASCULOGENESIS - the formation of vessels from “blood lakes”
![Page 24: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/24.jpg)
24
Noden – Am Rev Respir Dis. 1989
Processes involved in vessel development
SCL/tal-1 ARNTELF-1EPASFli-1GATA2GATA3HIF-1αHOXD3NERF-2
Ets-1Fra1Vezf1
Ets-1 AML-1COUP-TFIIHESR1HOXB3PPAR-γ
dHANDMEF2CSMAD5SmLIM
LKLF
Growth Factors and ReceptorsbFGFFlk-1Flt-1integrin αVß3
P/GHTGF-ßTIE2VEGF
Angiopoietin-1TIE2
Transcription Factors
PrimitiveMesenchyme
Hemangio-blasts
Endothelial CellCommitment
“Blood Island”Migration and
Tube Formation
Smooth MuscleRecruitment andDifferentiation
MatureBloodVessel
proteases
![Page 25: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/25.jpg)
25
Structure – Function Relationship
Am J Respir. Cell Mol. Biol., 16:568-581, 1997.
![Page 26: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/26.jpg)
26
Methods
Mercox
Right Ventricle
Pulmonary VascularCast
NORMAL LUNG TEM – 9 DAYS
2,800 X 8,750 X
![Page 27: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/27.jpg)
27
Normal LungTEM – 10 days
5,250 X
Normal LungMercox Vascular Cast
12 days 13 days
![Page 28: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/28.jpg)
28
Normal LungMercox Vascular Cast
16 days15 days
![Page 29: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/29.jpg)
29
3μ
15 days
3m
![Page 30: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/30.jpg)
30
CONCLUSION
Early events in mouse lung vascular development
ANGIOGENESIS
FUSION
VASCULOGENESIS
CIRCULATION ESTABLISHED
![Page 31: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/31.jpg)
31
Carnegie Collection of Human Embryos and Fetuses
housed in the
Human Developmental Anatomy Center
at the
National Museum of Health and Medicine
of the
Armed Forces Institute of Pathology , Washington, D.C.
Ped. Dev. Pathol. 3:439-449, 2000
32 days
Stage 14
![Page 32: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/32.jpg)
32
Stage 14
esophagus
bronchus
bronchus
50 ½ days
Stage 20
![Page 33: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/33.jpg)
33
Stage 22
54 days
22-23 weeks
![Page 34: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/34.jpg)
34
Human Lung Vascular Development: Processes involved
Angiogenesis
Vasculogenesis
Fusion
SCL/tal-1 ARNTELF-1EPASFli-1GATA2GATA3HIF-1αHOXD3NERF-2
Ets-1Fra1Vezf1
Ets-1 AML-1COUP-TFIIHESR1HOXB3PPAR-γ
dHANDMEF2CSMAD5SmLIM
LKLF
Growth Factors and ReceptorsbFGFFlk-1Flt-1integrin αVß3
P/GHTGF-ßTIE2VEGF
Angiopoietin-1TIE2
Transcription Factors
PrimitiveMesenchyme
Hemangio-blasts
Endothelial CellCommitment
“Blood Island”Migration and
Tube Formation
Smooth MuscleRecruitment andDifferentiation
MatureBloodVessel
proteases
![Page 35: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/35.jpg)
35
The VEGF 120/120 mouse
Am. J Respir.Cell Mol Biol. 27:194-203, 2002
Vascular Endothelial Growth Factor (VEGF)
• Best studied angiogenic growth factor
• Plays a critical role in stimulating vessel growth
• Deletion of even a single VEGF allele is lethal
• Three VEGF isoforms expressed in mouse lung
![Page 36: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/36.jpg)
36
Distribution of VEGF Isoformsin
Mouse lung
VEGF 12031%
VEGF 18846%
VEGF 16423%
VEGF 188
VEGF 120
VEGF 164
Conception Term
Relative Amounts of VEGF Isoformsin
Fetal Mouse Lung
![Page 37: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/37.jpg)
37
VEGF Gene
WILD TYPE
VEGF 120
3 4 5 6 7 8
Exons 6 and 7 deleted
VEGF Gene
WILD TYPE
VEGF 120
3 4 5 6 7 8
Exons 6 and 7 deleted
![Page 38: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/38.jpg)
38
Study Design
Swiss-Weber mouse fetuses (9-20 days gestation)
Study vessel developmental processes
TEM of lungspecimens
SEM of lungvascular casts
VEGF Genotyping
![Page 39: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/39.jpg)
39
17-day-old VEGF 120 Transgenic Fetal
Mouse Whole Body Vascular Casts
WILD TYPE
WILD TYPE HETEROZYGOUS HOMOZYGOUS
15-day-old VEGF120 Transgenic Fetal Mouse Lung Vascular Casts
![Page 40: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/40.jpg)
40
SEM of 15-day VEGF 120 Transgenic Fetal Mouse Lung Vascular Casts
WILD TYPE HETEROZYGOUS HOMOZYGOUS
MAG X 43
SEM of 15-day VEGF 120 Transgenic Fetal Mouse Lung Vascular Casts
WILD TYPE HETEROZYGOUS HOMOZYGOUS
MAG X 700
![Page 41: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/41.jpg)
41
WILD TYPE HETEROZYGOUS HOMOZYGOUS
17-day-old VEGF120 Transgenic FetalMouse Lung Vascular Casts
MAG X 230
SEM of 17-day VEGF 120 Transgenic Fetal Mouse Lung Vascular Casts
WILD TYPE HETEROZYGOUS HOMOZYGOUS
![Page 42: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/42.jpg)
42
18-day-old VEGF120 Transgenic FetalMouse Lung Vascular Casts
WILD TYPE HETEROZYGOUS HOMOZYGOUS
MAG X 140
SEM of 18-day VEGF 120 Transgenic Fetal Mouse Lung Vascular Casts
WILD TYPE HETEROZYGOUS HOMOZYGOUS
![Page 43: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/43.jpg)
43
1-day-old VEGF120 Transgenic Mouse Pup Lung Vascular Casts
WILD TYPE HETEROZYGOUS HOMOZYGOUS
SEM of Post Natal Day 1 VEGF 120 Transgenic Mouse Lung Vascular Casts
MAG X 700
WILD TYPE HETEROZYGOUS HOMOZYGOUS
![Page 44: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/44.jpg)
44
WT VEGF 120/120
*
*
* *
*
**
15-day Fetus
*
*
**
*
WT 120/12015-day Fetus
![Page 45: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/45.jpg)
45
HOMOZYGOUS 0.0516*
HETEROZYGOUS 0.0858
WILD TYPE 0.1168
Airway-Parenchymal Ratio
*p<0.02
15-day-old Mouse Fetuses
Post Natal Day 1WT 120/120
![Page 46: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/46.jpg)
46
HOMOZYGOUS 1.15*
HETEROZYGOUS 3.45
WILD TYPE 4.65
Number of Air-Blood Barriers
*p<0.0001
Postnatal 1-Day-Old Mouse Pups
Conclusion
Absence of VEGF 164 and 188 isoforms:
• impairs the development of the lung’smicrovasculature
• delays airspace structural maturation
![Page 47: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/47.jpg)
47
Clinical Summary
• Infant born at 41wks gestation, meconium staining noted
• Hypoxemia, respiratory difficulty shortly after birth
• ℞ with mechanical ventilation, NO, ECMO
• Death at two weeks of age
![Page 48: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/48.jpg)
48
Normal PPHN
![Page 49: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/49.jpg)
49
PPHN I - due to maldevelopment
Abnormal vascular structurepossibly a reflection of aberrant
angiogenesis
Unlikely to respond to ℞s
![Page 50: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/50.jpg)
50
PPHN II - due to maladaptation
Vascular structure normal, but absence of post-natal increase in pulmonary vascular compliance-
most likely to respond to℞s
Clinical Summary
• Infant born at 30 wks gestation
• Gasping respirations at birth
• Unable to ventilate
• Death in a few minutes
![Page 51: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/51.jpg)
51
![Page 52: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/52.jpg)
52
![Page 53: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/53.jpg)
53
Airway
Anatomic Findings
• Hypoplasia of pre-and intra-acinar pulmonary arteries
• Precocious muscularization
• Thick media and adventitia
• Interstitial emphysema
![Page 54: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/54.jpg)
54
Maternal Cocaine Use
PPHN III - due to hypoplastic pulmonary vascular tree
Underdevelopment of the pulmonary vasculature possibly a reflection of
aberrant angiogenesisUnlikely to respond to ℞s
![Page 55: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/55.jpg)
55
Disorders of lung growth- Vessels
• Abnormal vascular growth –PPHN /MAS
• Alveolar capillary dysplasia (ACD)/misalignment of vessels
• Congenital pulmonary lymphangiectasia
• Infant born at 36 wks gestation• Hypoxemia and apnea shortly after birth• Placed on ECMO for 2 wks• Could not be weaned• Death at 2 wks post-natal age
Clinical Summary
![Page 56: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/56.jpg)
56
Alveolar Capillary Dysplasia
ACDNormal
![Page 57: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/57.jpg)
57
![Page 58: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/58.jpg)
58
Alveolar space
capillary
ACD - EM
Functional Implications
• Impaired angiogenesis:– PPHN (III), hypoplastic vascular tree
– Absence of PA
– Misalignment of blood vessels
• Impaired vasculogenesis:– Alveolar capillary dysplasia
– Angiomatosis
• Abnormal fusion– Arteriovenous malformation
![Page 59: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/59.jpg)
59
Disorders of lung maturation
• Prematurity–deficiency of surfactant lipid and protein (HMD & SP-A deficiency)
• Pulmonary interstitial glycogenosis (PIG)
• Congenital alveolar proteinosis
- SP-B deficiency
- SP-C deficiency
- GM-CSF mutation
- ABCA3 mutation
Pulmonary alveolar proteinosis
• Congenital AP
SP-B deficiency
SP-C deficiency
ABCA3 Mutation
GM-CSF/ GM-CSF 3/5 - Receptor deficiency
• Acquired AP
![Page 60: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/60.jpg)
60
Clinical Summary
• Full term newborn develops severe respiratory distress shortly after birth
• with survanta, O2, ventilation, ECMO• Lung biopsy• Death shortly thereafter, no autopsy
H&E SP-A
SP-B SP-C
![Page 61: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/61.jpg)
61
SP-B deficiency - absent transcripts
SP-B deficiency
![Page 62: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/62.jpg)
62
SP-B deficiency – index family
SP-B mutations
![Page 63: Faculty Disclosure Information - Draeger · Faculty Disclosure Information • I have no financial relationship with any manufacturer of any commercial product and/or provider of](https://reader030.fdocuments.us/reader030/viewer/2022040717/5e228c12d2d3e271c931ed09/html5/thumbnails/63.jpg)
63